Regulatory T cells (Tregs) play a pivotal role in maintaining immune homeostasis and preventing autoimmunity. Treg-based cell therapies have already shown efficient modulation of immune responses in several clinical settings. However, the complexity and the cost of manufacturing autologous cell products restricts their implementation to certain patient populations with the highest unmet need. Induced pluripotent stem cells (iPSCs) have emerged as suitable starting material for generating diverse cell types, including Tregs.

This abstract, authored by Quell and Cellistic, highlights our joint efforts in deriving iPSC-based Tregs and characterizing their functionality for potential therapeutic applications.

Results demonstrate the successful derivation of functional iPSC-Tregs exhibiting potent suppressive activity. Flow cytometry and epigenetic analyses confirm the identity of the Treg lineage, reinforcing the fidelity of our differentiation protocol. This study provides a robust platform for the derivation and functional characterization of iPSC-Tregs, paving the path towards their potential application in cell therapy against autoimmune, metabolic, and other inflammatory diseases.

 

ESCT 2024 Poster allo
Authors: Marco Romano1, Eva D’Amico2, Sim Tung1, Manoj Gautam2, Evanthia Nikolopoulou1, Virginie Stygelbout2, Sophie Howson1, Suzanne Snellenberg2, Sean R. Holm1, Momchil I. Popov1, Elena Matsa2, Stefan Braam2, Marc Martinez-Llordella1

Quell Therapeutics, London, United Kingdom                                                                                         
Cellistic, Mont-Saint-Guibert, Belgium
ESCT 2024 Poster allo

Download the Poster

 

Don’t hesitate to contact us via the form below if you want to learn more about iPSCs and Cellistic's approach.